Detalhe da pesquisa
1.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
J Transl Med
; 12: 277, 2014 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25348889
2.
Tim-3 finds its place in the cancer immunotherapy landscape.
J Immunother Cancer
; 8(1)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32601081
3.
Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background.
Front Immunol
; 10: 3115, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32010149
4.
The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis.
Front Immunol
; 6: 541, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26557120
5.
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
J Immunother Cancer
; 8(1)2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32300051
6.
Tim-3, a negative regulator of anti-tumor immunity.
Curr Opin Immunol
; 24(2): 213-6, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22226204
7.
Editorial: Tim-3 puts on the brakes.
J Leukoc Biol
; 91(2): 183-5, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22293940